News
-
MOTS-c Dosage: Why There Is No Standard Dose
There is no established human MOTS-c dose. Published human research is mostly observational, and the numbers repeated online come largely from mouse experiments rather than clinical dosing trials.
-
Tirzepatide Brand Names: Mounjaro and Zepbound
The two U.S. tirzepatide brand names are Mounjaro and Zepbound, both made by Eli Lilly. They contain the same active ingredient but carry different approved uses; compounded tirzepatide is not a brand.
-
Semaglutide Pill vs Injection: What Exists
There is a semaglutide pill. There is no tirzepatide pill, and there is unlikely to be one. Understanding why comes down to what happens to a 39-amino-acid peptide in your stomach.
-
Microdosing Tirzepatide: What It Means
No trial has ever tested it, and the term has no clinical definition. That does not make it unreasonable — but it does change what you can honestly expect from it.
-
Sermorelin Benefits: What the Trials Found
In the best controlled study of GHRH in older adults, nocturnal growth hormone rose, IGF-1 climbed within two weeks, skin thickened — and lean body mass increased in men only. The specificity is the point.
-
Tirzepatide Cost: What You Actually Pay
The brand-name list price runs about $1,086 a month. Almost nobody pays it — and the gap between that number and what you are actually quoted is where most of the confusion lives.
-
BPC-157 Side Effects and the Evidence Gap
[FDA's July 2026 briefing](https://www.fda.gov/media/193343/download) identifies three indexed uncontrolled reports describing BPC-157 exposure in 31 people, plus two older controlled enema studies reported only as meeting abstracts. That limited record, more than any list of symptoms, is the honest answer to what its side effects are.
-
Semaglutide Dosage: The 17-Week Ladder
The Wegovy injection schedule for weight management climbs through five doses over sixteen weeks before reaching 2.4 mg. That deliberate pace is the single best-supported way to make the first months tolerable.
-
Sermorelin Side Effects, by the Numbers
About one patient in six gets a reaction where the needle went in. Almost everything else on the list occurs in under 1% — but the trial data behind those numbers comes from a population that may not look like you.
-
Tirzepatide Dosage and the Titration Ladder
Every tirzepatide dose ladder starts at 2.5 mg and climbs in 2.5 mg steps no sooner than every four weeks. Understanding why that interval exists tells you most of what you need to know about your own schedule.
-
Tirzepatide Side Effects, From Common to Rare
Gastrointestinal effects are the ones almost everyone asks about — and across the tirzepatide dose range they affect 39% to 49% of people, concentrated in the weeks when the dose is going up.
-
Ipamorelin Benefits, Side Effects, Legal Status
Developed at Novo Nordisk in the late 1990s, ipamorelin is a five-amino-acid peptide that released growth hormone in animal studies without raising cortisol even at more than 200 times its effective dose.
-
Retatrutide and the Rise of the Triple Agonist
In its 48-week phase-2 obesity trial, retatrutide's highest dose produced an average 24.2% body-weight reduction — at publication, the largest average weight loss any obesity drug trial had reported.
-
Epitalon Benefits, Sorted by Evidence Tier
The most-cited animal experiment gave 54 mice per group monthly doses for life and found mean lifespan unchanged, maximum lifespan up 12.3%, and leukemia down six-fold.
-
Semaglutide Side Effects, From Common to Rare
Across pooled STEP-trial safety data, only 4.3% of adults taking semaglutide 2.4 mg stopped treatment because of gastrointestinal side effects.
-
Oxytocin Peptide Beyond the 'Love Hormone'
A 2025 meta-analysis pooling 20 effect estimates from 13 human studies found no overall effect of oxytocin on non-social executive function — one number that explains why this molecule's science reads nothing like its nickname.
-
The Thymulin Peptide Needs Zinc to Work
Thymulin is inert until a zinc ion binds it at a 1:1 molar ratio — and most published results in its literature come from mice, rats, or cell culture.
-
Inside the Glow Peptide Blend
Glow combines three peptides with non-overlapping jobs — BPC-157 signals new blood-vessel growth, TB-500 binds the cell-scaffolding protein actin, and GHK-Cu delivers copper to the enzyme that cross-links collagen.
-
AOD-9604 Peptide: Fat-Loss Hype vs the Record
Six placebo-controlled trials in 893 obese adults — capped by a 536-subject study that missed its endpoints — ended AOD-9604's drug development in 2007.
-
What Is Selank Used For?
Selank is a Russian-developed heptapeptide studied mostly for anxiety, and its pivotal human trial put 62 patients with generalized anxiety disorder and neurasthenia head to head against the benzodiazepine medazepam.
Page 16 of 18 · 344 articles